Guowei Xia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2997165/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 50.e1-50.e8.	1.6	58
2	Ki-67 is an independent indicator in non–muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 42.e13-42.e19.	1.6	46
3	Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3. Cancer Research, 2016, 76, 3277-3284.	0.9	46
4	Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. Frontiers in Oncology, 2021, 11, 693517.	2.8	46
5	Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Science, 2011, 9, 22.	1.7	37
6	COPB2 Is Upregulated in Prostate Cancer and Regulates PC-3 Cell Proliferation, Cell Cycle, and Apoptosis. Archives of Medical Research, 2016, 47, 411-418.	3.3	30
7	A functional variant in <scp><i>TP</i></scp> <i>63</i> at 3q28 associated with bladder cancer risk by creating an mi <scp>R</scp> â€140â€5p binding site. International Journal of Cancer, 2016, 139, 65-74.	5.1	27
8	Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World Journal of Urology, 2015, 33, 1951-1957.	2.2	20
9	Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells. Experimental and Therapeutic Medicine, 2017, 14, 3513-3518.	1.8	15
10	Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells. Biochemical and Biophysical Research Communications, 2018, 495, 473-480.	2.1	15
11	Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer?. Cancer Epidemiology, 2014, 38, 157-161.	1.9	13
12	Characterization and validation of long noncoding RNAs as new candidates in prostate cancer. Cancer Cell International, 2020, 20, 531.	4.1	7
13	Potential Alterations of Functional Connectivity Analysis in the Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Neural Plasticity, 2021, 2021, 1-9.	2.2	5
14	Differential expression profiles of circRNAs in human prostate cancer based on chip and bioinformatic analysis. International Journal of Clinical and Experimental Pathology, 2020, 13, 1045-1052.	0.5	5
15	Retroperitoneal Laparoscopic Ureterolithotomy for Proximal Ureteral Calculi in Selected Patients. Scientific World Journal, The, 2014, 2014, 1-5.	2.1	4
16	Postoperative renormalization of C-reactive protein with adjuvant lienal polypeptide and its association with tumour recurrence in T1 clear cell renal cell carcinoma. Journal of International Medical Research, 2016, 44, 620-626.	1.0	4
17	NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP. Chemotherapy, 2018, 63, 191-197.	1.6	3
18	High-level expression of periostin is significantly correlated with tumor angiogenesis in prostate cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 1569-1574.	0.5	2

#	Article	IF	CITATIONS
19	Lysine demethylase 5A promotes prostate adenocarcinoma progression by suppressing microRNA-330-3p expression and activating the COPB2/PI3K/AKT axis in an ETS1-dependent manner. Journal of Cell Communication and Signaling, 2022, 16, 579-599.	3.4	2
20	A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy. Annals of Clinical and Laboratory Science, 2018, 48, 18-28.	0.2	1